Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8)

dc.contributor.author
Porquet Costa, David
dc.contributor.author
Andrés Benito, Pol
dc.contributor.author
Griñán Ferré, Christian
dc.contributor.author
Camins Espuny, Antoni
dc.contributor.author
Ferrer, Isidro (Ferrer Abizanda)
dc.contributor.author
Canudas Teixidó, Anna-Maria
dc.contributor.author
Valle i Macià, Jaume del
dc.contributor.author
Pallàs i Llibería, Mercè, 1964-
dc.date.issued
2018-10-29T12:07:31Z
dc.date.issued
2018-10-29T12:07:31Z
dc.date.issued
2015-02-08
dc.date.issued
2018-10-29T12:07:32Z
dc.identifier
0161-9152
dc.identifier
https://hdl.handle.net/2445/125694
dc.identifier
647694
dc.identifier
25663420
dc.description.abstract
The amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of Alzheimer's disease (AD) has provided robust neuropathological hallmarks of familial AD-like pattern at early ages, whereas senescence-accelerated mouse prone 8 (SAMP8) has a remarkable early senescence phenotype with pathological similarities to AD. The aim of this study was the investigation and characterization of cognitive and neuropathological AD markers in a novel mouse model that combines the characteristics of the APP/PS1 transgenic mouse model with a senescence-accelerated background of SAMP8 mice. Initially, significant differences were found regarding amyloid plaque formation and cognitive abnormalities. Bearing these facts in mind, we determined a general characterization of the main AD brain molecular markers, such as alterations in amyloid pathway, neuroinflammation, and hyperphosphorylation of tau in these mice along their lifetimes. Results from this analysis revealed that APP/PS1 in SAMP8 background mice showed alterations in the pathways studied in comparison with SAMP8 and APP/PS1, demonstrating that a senescence-accelerated background exacerbated the amyloid pathology and maintained the cognitive dysfunction present in APP/PS1 mice. Changes in tau pathology, including the activity of cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3 β (GSK3β), differs, but not in a parallel manner, with amyloid disturbances.
dc.format
application/pdf
dc.language
eng
dc.publisher
Springer Verlag
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1007/s11357-015-9747-3
dc.relation
AGE, 2015, vol. 37, num. 1, p. 12
dc.relation
https://doi.org/10.1007/s11357-015-9747-3
dc.rights
(c) American Aging Association, 2015
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Malaltia d'Alzheimer
dc.subject
Malalties neurodegeneratives
dc.subject
Alzheimer's disease
dc.subject
Neurodegenerative Diseases
dc.title
Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8)
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.